DavidJVanderweeleMDPhD

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Hematology and Oncology, Northwestern University Feinberg School of Medicine

Dr. Vanderweele is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of ChicagoFellowship, Hematology and Medical Oncology, 2009 - 2012
University of ChicagoResidency, Internal Medicine, 2007 - 2009
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2007

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostat...
Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, Matthew Rettig, Elisabeth I Heath
Journal of Clinical Oncology. 2025-03-26
Response to pembrolizumab in advanced prostate cancer with predictive biomarkers.
Nicole J Altomare, Yutai Li, Clayton Neill, Maha Hussain, David J VanderWeele
The Oncologist. 2025-03-10
Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.
John S Wang, Jack C Shapiro, Sarah Orlando, Rusul Al-Marayaty, Farres Obeidin
Journal of Cancer Research and Clinical Oncology. 2025-02-10

Lectures

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Combination Treatment Extends Survival in Advanced Bladder CancerSeptember 17th, 2024
Combination Treatment Extends Survival in Locally Advanced Bladder CancerSeptember 15th, 2024